GlassScriptPhysician profile
Deborah E Haynes
NPI 1104807395
$3,564.02
in general payments reported to CMS, 2019-2025
30 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $389 · 2021: $892 · 2022: $1,160 · 2023: $352 · 2024: $220 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.19 | 2019-2022 | |
| Daiichi Sankyo INC. | $429.53 | 2019-2025 | Injectafer |
| Hologic Sales and Service, LLC | $391.93 | 2019-2023 | Aptima |
| Aspira Women'S Health INC | $352.99 | 2022 | |
| Mayne Pharma Commercial LLC | $327.06 | 2021-2025 | |
| Astellas Pharma US INC | $317.69 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $260.93 | 2021-2022 | |
| Agile Therapeutics, INC. | $163.40 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.25 | 2019-2025 | |
| Organon LLC | $87.37 | 2024-2025 | Jada System, Nexplanon |
| Mylan Pharmaceuticals INC. | $85.22 | 2019-2021 | |
| Millicent US INC | $63.58 | 2020-2025 | Femring, Intrarosa |
| Merck Sharp & Dohme LLC | $54.59 | 2019-2020 | |
| Evofem Biosciences, INC. | $50.17 | 2021 | |
| Sumitomo Pharma America, INC. | $47.84 | 2023-2024 | Myfembree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $46.38 | 2020 | |
| Myovant Sciences INC. | $41.21 | 2021-2022 | |
| Exeltis, USA INC. | $33.98 | 2020-2021 | |
| Boston Scientific Corporation | $30.59 | 2019-2022 | |
| Avion Pharmaceuticals | $25.30 | 2019-2022 | |
| Ascend Therapeutics US, LLC | $24.82 | 2023 | |
| Amgen INC. | $23.38 | 2022 | |
| Dexcom, INC. | $22.40 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $19.77 | 2023 | Bd Onclarity |
| Pfizer INC. | $18.69 | 2024 | |
| Medtronic, INC. | $15.20 | 2021 | |
| Therapeuticsmd, INC. | $14.11 | 2020 | |
| Avanos Medical | $12.58 | 2019 | |
| Lupin INC. | $11.34 | 2019 | |
| Channel Medsystems, INC. | $9.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Haynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.